Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture

Wierzbicka,J. M.; Binek,A.; Ahrends,T.; Nowacka,J. D.; Szydłowska,A.; Turczyk,Ł.; Wąsiewicz,T.; Wierzbicki,P. M.; Sądej,R.; Tuckey,R. C.; Slominski,A. T.; Chybicki,J.; Adrych,K.; Kmieć,Z.; Żmijewski,M. A.

doi:10.3892/ijo.2015.3088

Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture

Authors:
- J. M. Wierzbicka
- A. Binek
- T. Ahrends
- J. D. Nowacka
- A. Szydłowska
- Ł. Turczyk
- T. Wąsiewicz
- P. M. Wierzbicki
- R. Sądej
- R. C. Tuckey
- A. T. Slominski
- J. Chybicki
- K. Adrych
- Z. Kmieć
- M. A. Żmijewski
View Affiliations

Affiliations: Department of Histology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland, Students Scientific Association BIO‑MED, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland, Department of Molecular Enzymology, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland, School of Chemistry and Biochemistry, The University of Western Australia, Crawley WA, Australia, Department of Dermatology, University of Alabama Birmingham, VA Medical Center, Birmingham, AL 35294, USA, Department of General Surgery, Hospital Ministry Internal Affairs, 80104 Gdańsk, Poland, Department of Hepatology and Gastroenterology, Faculty of Medicine, Medical University of Gdańsk, 80210 Gdańsk, Poland
Published online on: July 17, 2015 https://doi.org/10.3892/ijo.2015.3088
Pages: 1084-1096

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is an emerging global problem with the rapid increase in its incidence being associated with an unhealthy lifestyle. Epidemiological studies have shown that decreased levels of vitamin D3 significantly increases the risk of CRC. Furthermore, negative effects of vitamin D3 deficiency can be compensated by appropriate supplementation. Vitamin D3 was shown to inhibit growth and induce differentiation of cancer cells, however, excessive vitamin D3 intake leads to hypercalcemia. Thus, development of efficient vitamin D3 analogues with limited impact on calcium homeostasis is an important scientific and clinically relevant task. The aims of the present study were to compare the antiproliferative potential of classic vitamin D3 metabolites (1α,25(OH)2D3 and 25(OH)D3) with selected low calcemic analogues (calcipotriol and 20(OH)D3) on CRC cell lines and to investigate the expression of vitamin D-related genes in CRC cell lines and clinical samples. Vitamin D3 analogues exerted anti-proliferative effects on all CRC cell lines tested. Calcipotriol proved to be as potent as 1α,25(OH)2D3 and had more efficacy than 20-hydroxyvitamin D3. In addition, the analogs tested effectively inhibited the formation of colonies in Matrigel. The expression of genes involved in 1α,25(OH)2D3 signaling and metabolism varied in cell lines analysed, which explains in part their different sensitivities to the various analogues. In CRC biopsies, there was decreased VDR expression in tumor samples in comparison to the surgical margin and healthy colon samples (p<0.01). The present study indicates that vitamin D3 analogues which have low calcemic activity, such as calcipotriol or 20(OH)D3, are very promising candidates for CRC therapy. Moreover, expression profiling of vitamin D-related genes is likely to be a powerful tool in the planning of anticancer therapy. Decreased levels of VDR and increased CYP24A1 expression in clinical samples underline the importance of deregulation of vitamin D pathways in the development of CRC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	López-Gómez M, Malmierca E, de Górgolas M and Casado E: Cancer in developing countries: The next most preventable pandemic. The global problem of cancer. Crit Rev Oncol Hematol. 88:117–122. 2013. View Article : Google Scholar : PubMed/NCBI
3	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008. View Article : Google Scholar : PubMed/NCBI
4	Johnston PG and Kaye S: Capecitabine: A novel agent for the treatment of solid tumors. Anticancer Drugs. 12:639–646. 2001. View Article : Google Scholar : PubMed/NCBI
5	Liu G, Hu X and Chakrabarty S: Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: Downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer. 126:631–639. 2010. View Article : Google Scholar
6	Milczarek M, Psurski M, Kutner A and Wietrzyk J: Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer. 13:2942013. View Article : Google Scholar : PubMed/NCBI
7	Holick MF, Frommer JE, McNeill SC, Richtand NM, Henley JW and Potts JT Jr: Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochem Biophys Res Commun. 76:107–114. 1977. View Article : Google Scholar : PubMed/NCBI
8	Holick MF, DeLuca HF and Avioli LV: Isolation and identification of 25-hydroxycholecalciferol from human plasma. Arch Intern Med. 129:56–61. 1972. View Article : Google Scholar : PubMed/NCBI
9	Holick MF, Schnoes HK, DeLuca HF, Gray RW, Boyle IT and Suda T: Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney. Biochemistry. 11:4251–4255. 1972. View Article : Google Scholar : PubMed/NCBI
10	Holick MF, Schnoes HK, DeLuca HF, Suda T and Cousins RJ: Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry. 10:2799–2804. 1971. View Article : Google Scholar : PubMed/NCBI
11	Hewison M, Zehnder D, Chakraverty R and Adams JS: Vitamin D and barrier function: A novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol. 215:31–38. 2004. View Article : Google Scholar : PubMed/NCBI
12	Tieu EW, Tang EKY, Tuckey RC and Adams JS: Kinetic analysis of human CYP24A1 metabolism of vitamin D via the C24-oxidation pathway. FEBS J. 281:3280–3296. 2014. View Article : Google Scholar : PubMed/NCBI
13	Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE and Jurutka PW: The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res. 13:325–349. 1998. View Article : Google Scholar : PubMed/NCBI
14	Slominski A, Zjawiony J, Wortsman J, Semak I, Stewart J, Pisarchik A, Sweatman T, Marcos J, Dunbar C and Tuckey RC: A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem. 271:4178–4188. 2004. View Article : Google Scholar : PubMed/NCBI
15	Slominski A, Semak I, Zjawiony J, Wortsman J, Li W, Szczesniewski A and Tuckey RC: The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J. 272:4080–4090. 2005. View Article : Google Scholar : PubMed/NCBI
16	Guryev O, Carvalho RA, Usanov S, Gilep A and Estabrook RW: A pathway for the metabolism of vitamin D3: Unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc Natl Acad Sci USA. 100:14754–14759. 2003. View Article : Google Scholar : PubMed/NCBI
17	Slominski A, Semak I, Wortsman J, Zjawiony J, Li W, Zbytek B and Tuckey RC: An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2. FEBS J. 273:2891–2901. 2006. View Article : Google Scholar : PubMed/NCBI
18	Slominski AT, Li W, Kim TK, Semak I, Wang J, Zjawiony JK and Tuckey RC: Novel activities of CYP11A1 and their potential physiological significance. J Steroid Biochem Mol Biol. 151:25–37. 2015. View Article : Google Scholar
19	Slominski AT, Kim TK, Shehabi HZ, Semak I, Tang EK, Nguyen MN, Benson HA, Korik E, Janjetovic Z, Chen J, et al: In vivo evidence for a novel pathway of vitamin D₃ metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 26:3901–3915. 2012. View Article : Google Scholar : PubMed/NCBI
20	Slominski AT, Kim TK, Shehabi HZ, Tang EK, Benson HA, Semak I, Lin Z, Yates CR, Wang J, Li W, et al: In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland. Mol Cell Endocrinol. 383:181–192. 2014. View Article : Google Scholar : PubMed/NCBI
21	Slominski AT, Janjetovic Z, Kim TK, Wasilewski P, Rosas S, Hanna S, Sayre RM, Dowdy JC, Li W and Tuckey RC: Novel non-calcemic secosteroids that are produced by human epidermal keratinocytes protect against solar radiation. J Steroid Biochem Mol Biol. 148:52–63. 2015. View Article : Google Scholar : PubMed/NCBI
22	Slominski AT, Kim TK, Li W, Yi AK, Postlethwaite A and Tuckey RC: The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J Steroid Biochem Mol Biol. 144:28–39. 2014. View Article : Google Scholar
23	Slominski A, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya KG, Wang J, Li W, Jiao Y, Gu W, Brown M, et al: 20S-hydroxyvitamin D₃, noncalcemic product of CYP11A1 action on vitamin D₃, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab. 98:E298–E303. 2013. View Article : Google Scholar : PubMed/NCBI
24	Slominski AT, Kim TK, Chen J, Nguyen MN, Li W, Yates CR, Sweatman T, Janjetovic Z and Tuckey RC: Cytochrome P450scc-dependent metabolism of 7-dehydrocholesterol in placenta and epidermal keratinocytes. Int J Biochem Cell Biol. 44:2003–2018. 2012. View Article : Google Scholar : PubMed/NCBI
25	Slominski AT, Kim TK, Janjetovic Z, Tuckey RC, Bieniek R, Yue J, Li W, Chen J, Nguyen MN, Tang EK, et al: 20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am J Physiol Cell Physiol. 300:C526–C541. 2011. View Article : Google Scholar :
26	Slominski AT, Janjetovic Z, Fuller BE, Zmijewski MA, Tuckey RC, Nguyen MN, Sweatman T, Li W, Zjawiony J, Miller D, et al: Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. PLoS One. 5:e99072010. View Article : Google Scholar : PubMed/NCBI
27	Slominski AT, Kim TK, Takeda Y, Janjetovic Z, Brozyna AA, Skobowiat C, Wang J, Postlethwaite A, Li W, Tuckey RC, et al: RORα and RORγ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy-and 20,23-dihydroxyvitamin D. FASEB J. 28:2775–2789. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zbytek B, Janjetovic Z, Tuckey RC, Zmijewski MA, Sweatman TW, Jones E, Nguyen MN and Slominski AT: 20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol. 128:2271–2280. 2008. View Article : Google Scholar : PubMed/NCBI
29	Slominski AT, Janjetovic Z, Kim TK, Wright AC, Grese LN, Riney SJ, Nguyen MN and Tuckey RC: Novel vitamin D hydroxy-derivatives inhibit melanoma growth and show differential effects on normal melanocytes. Anticancer Res. 32:3733–3742. 2012.PubMed/NCBI
30	Janjetovic Z, Brozyna AA, Tuckey RC, Kim TK, Nguyen MN, Jozwicki W, Pfeffer SR, Pfeffer LM and Slominski AT: High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br J Cancer. 105:1874–1884. 2011. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Slominski A, Tuckey RC, Janjetovic Z, Kulkarni A, Chen J, Postlethwaite AE, Miller D and Li W: 20-hydroxyvitamin D₃ inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res. 32:739–746. 2012.PubMed/NCBI
32	Holick MF: Vitamin D and bone health. J Nutr. 126(Suppl): 1159S–1164S. 1996.PubMed/NCBI
33	Hayes CE, Nashold FE, Spach KM and Pedersen LB: The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 49:277–300. 2003.
34	Pálmer HG, Sánchez-Carbayo M, Ordóñez-Morán P, Larriba MJ, Cordón-Cardó C and Muñoz A: Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D₃ in human colon cancer cells. Cancer Res. 63:7799–7806. 2003.
35	Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ and Evans SR: 1,25-Dihydroxyvitamin D₃ receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53:3712–3718. 1993.PubMed/NCBI
36	Leyssens C, Verlinden L and Verstuyf A: The future of vitamin D analogs. Front Physiol. 5:1222014. View Article : Google Scholar : PubMed/NCBI
37	Hansen CM, Hamberg KJ, Binderup E and Binderup L: Seocalcitol (EB 1089): A vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des. 6:803–828. 2000. View Article : Google Scholar : PubMed/NCBI
38	Slominski AT and Carlson JA: Melanoma resistance: A bright future for academicians and a challenge for patient advocates. Mayo Clin Proc. 89:429–433. 2014. View Article : Google Scholar : PubMed/NCBI
39	Bikle DD: Vitamin D: An ancient hormone. Exp Dermatol. 20:7–13. 2011. View Article : Google Scholar : PubMed/NCBI
40	Brown AJ, Dusso A and Slatopolsky E: Vitamin D. Am J Physiol. 277:F157–F175. 1999.PubMed/NCBI
41	Ebert R, Schütze N, Adamski J and Jakob F: Vitamin D signaling is modulated on multiple levels in health and disease. Mol Cell Endocrinol. 248:149–159. 2006. View Article : Google Scholar : PubMed/NCBI
42	Whitfield GK, Jurutka PW, Haussler CA, Hsieh JC, Barthel TK, Jacobs ET, Encinas Dominguez C, Thatcher ML and Haussler MR: Nuclear vitamin D receptor: structure-function, molecular control of gene transcription, and novel bioactions. Vitamin D. 2nd edition. Feldman D, Pike JW and Glorieux FH: Elsevier Academic Press; Oxford: pp. 219–261. 2005, View Article : Google Scholar
43	Khanal R and Nemere I: Membrane receptors for vitamin D metabolites. Crit Rev Eukaryot Gene Expr. 17:31–47. 2007. View Article : Google Scholar : PubMed/NCBI
44	Bouvier M: Accessory proteins and the assembly of human class I MHC molecules: A molecular and structural perspective. Mol Immunol. 39:697–706. 2003. View Article : Google Scholar : PubMed/NCBI
45	Eufemi M, Coppari S, Altieri F, Grillo C, Ferraro A and Turano C: ERp57 is present in STAT3-DNA complexes. Biochem Biophys Res Commun. 323:1306–1312. 2004. View Article : Google Scholar : PubMed/NCBI
46	Ozkan B, Hatun S and Bereket A: Vitamin D intoxication. Turk J Pediatr. 54:93–98. 2012.PubMed/NCBI
47	Wierzbicka J, Piotrowska A and Żmijewski MA: The renaissance of vitamin D. Acta Biochim Pol. 61:679–686. 2014.
48	Wierzbicki PM, Adrych K, Kartanowicz D, Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I, Celinski K, Gach T, Kulig J, et al: Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol. 19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI
49	Wierzbicki PM, Klacz J, Rybarczyk A, Slebioda T, Stanislawowski M, Wronska A, Kowalczyk A, Matuszewski M and Kmiec Z: Identification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma. Tumour Biol. 35:12473–12487. 2014. View Article : Google Scholar : PubMed/NCBI
50	Ren S, Nguyen L, Wu S, Encinas C, Adams JS and Hewison M: Alternative splicing of vitamin D-24-hydroxylase: A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem. 280:20604–20611. 2005. View Article : Google Scholar : PubMed/NCBI
51	Binderup L: Comparison of calcipotriol with selected metabolites and analogues of vitamin D3: Effects on cell growth regulation in vitro and calcium metabolism in vivo. Pharmacol Toxicol. 72:240–244. 1993. View Article : Google Scholar : PubMed/NCBI
52	Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H and Mori M: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar
53	Tuohimaa P, Wang JH, Khan S, Kuuslahti M, Qian K, Manninen T, Auvinen P, Vihinen M and Lou YR: Gene expression profiles in human and mouse primary cells provide new insights into the differential actions of vitamin D3 metabolites. PLoS One. 8:e753382013. View Article : Google Scholar : PubMed/NCBI
54	Benton G, Arnaoutova I, George J, Kleinman HK and Koblinski J: Matrigel: From discovery and ECM mimicry to assays and models for cancer research. Adv Drug Deliv Rev. 79–80:3–18. 2014. View Article : Google Scholar
55	Evans SR, Schwartz AM, Shchepotin EI, Uskokovic M and Shchepotin IB: Growth inhibitory effects of 1,25-dihydroxyvitamin D₃ and its synthetic analogue, 1α,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft. Clin Cancer Res. 4:2869–2876. 1998.PubMed/NCBI
56	Cross HS, Bises G, Lechner D, Manhardt T and Kállay E: The Vitamin D endocrine system of the gut - its possible role in colorectal cancer prevention. J Steroid Biochem Mol Biol. 97:121–128. 2005. View Article : Google Scholar : PubMed/NCBI
57	Milczarek M, Filip-Psurska B, Swiętnicki W, Kutner A and Wietrzyk J: Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep. 32:491–504. 2014.PubMed/NCBI
58	Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A and Wietrzyk J: Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res. 33:433–444. 2013.PubMed/NCBI
59	Tanaka Y, Bush KK, Klauck TM and Higgins PJ: Enhancement of butyrate-induced differentiation of HT-29 human colon carcinoma cells by 1,25-dihydroxyvitamin D3. Biochem Pharmacol. 38:3859–3865. 1989. View Article : Google Scholar : PubMed/NCBI
60	Cross HS, Farsoudi KH and Peterlik M: Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25-dihydroxyvitamin D3 and two synthetic analogs: Relation to in vitro hypercalcemic potential. Naunyn Schmiedebergs Arch Pharmacol. 347:105–110. 1993. View Article : Google Scholar : PubMed/NCBI
61	Höbaus J, Fetahu IS, Khorchide M, Manhardt T and Kallay E: Epigenetic regulation of the 1,25-dihydroxyvitamin D₃ 24-hydroxylase (CYP24A1) in colon cancer cells. J Steroid Biochem Mol Biol. 136:296–299. 2013. View Article : Google Scholar
62	Mordan-McCombs S, Valrance M, Zinser G, Tenniswood M and Welsh J: Calcium, vitamin D and the vitamin D receptor: Impact on prostate and breast cancer in preclinical models. Nutr Rev. 65:S131–S133. 2007. View Article : Google Scholar : PubMed/NCBI
63	Peleg S and Nguyen CV: The importance of nuclear import in protection of the vitamin D receptor from polyubiquitination and proteasome-mediated degradation. J Cell Biochem. 110:926–934. 2010. View Article : Google Scholar : PubMed/NCBI
64	Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D, Johnston S, Tenesa A, Campbell H and Dunlop MG: Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 32:2430–2439. 2014. View Article : Google Scholar : PubMed/NCBI
65	Köstner K, Denzer N, Müller CS, Klein R, Tilgen W and Reichrath J: The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer Res. 29:3511–3536. 2009.PubMed/NCBI
66	Laczmanska I, Laczmanski L, Bebenek M, Karpinski P, Czemarmazowicz H, Ramsey D, Milewicz A and Sasiadek MM: Vitamin D receptor gene polymorphisms in relation to the risk of colorectal cancer in the Polish population. Tumour Biol. 35:12397–12401. 2014. View Article : Google Scholar : PubMed/NCBI
67	Vandewalle B, Adenis A, Hornez L, Revillion F and Lefebvre J: 1,25-dihydroxyvitamin D₃ receptors in normal and malignant human colorectal tissues. Cancer Lett. 86:67–73. 1994. View Article : Google Scholar : PubMed/NCBI
68	Brożyna AA, Jozwicki W, Janjetovic Z and Slominski AT: Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol. 42:618–631. 2011. View Article : Google Scholar
69	Brożyna AA, Jóźwicki W and Slominski AT: Decreased VDR expression in cutaneous melanomas as marker of tumor progression: New data and analyses. Anticancer Res. 34:2735–2743. 2014.
70	Reichrath J, Rech M, Moeini M, Meese E, Tilgen W and Seifert M: In vitro comparison of the vitamin D endocrine system in 1,25(OH)₂D₃-responsive and -resistant melanoma cells. Cancer Biol Ther. 6:48–55. 2007. View Article : Google Scholar
71	Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 25:144–146. 2000. View Article : Google Scholar : PubMed/NCBI
72	Brożyna AA, Jochymski C, Janjetovic Z, Jóźwicki W, Tuckey RC and Slominski AT: CYP24A1 expression inversely correlates with melanoma progression: Clinic-pathological studies. Int J Mol Sci. 15:19000–19017. 2014. View Article : Google Scholar
73	Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF and Chen TC: Vitamin D metabolism in human prostate cells: Implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 26:2567–2572. 2006.PubMed/NCBI
74	Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM and Hewison M: Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 86:888–894. 2001.PubMed/NCBI
75	Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E and Peterlik M: 25-Hydroxyvitamin D₃-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids. 66:287–292. 2001. View Article : Google Scholar : PubMed/NCBI
76	Bareis P, Bises G, Bischof MG, Cross HS and Peterlik M: 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun. 285:1012–1017. 2001. View Article : Google Scholar : PubMed/NCBI
77	Bises G, Kállay E, Weiland T, Wrba F, Wenzl E, Bonner E, Kriwanek S, Obrist P and Cross HS: 25-hydroxyvitamin D₃-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem. 52:985–989. 2004. View Article : Google Scholar : PubMed/NCBI
78	Brożyna AA, Jóźwicki W, Jochymski C and Slominski AT: Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas. Oncol Rep. 33:599–606. 2015.
79	Brożyna AA, Jóźwicki W, Janjetovic Z and Slominski AT: Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression. Hum Pathol. 44:374–387. 2013. View Article : Google Scholar
80	Brown AJ and Slatopolsky E: Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med. 29:433–452. 2008. View Article : Google Scholar : PubMed/NCBI
81	Kim TK, Wang J, Janjetovic Z, Chen J, Tuckey RC, Nguyen MN, Tang EK, Miller D, Li W and Slominski AT: Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength. Mol Cell Endocrinol. 361:143–152. 2012. View Article : Google Scholar : PubMed/NCBI